Fees are a weakness here. The strategy's lofty fees are a high hurdle to clear, as it is priced within the second-highest quintile among peers.
Hartford Healthcare HLS IB HBGHX
- NAV / 1-Day Return 14.77 / −0.14 %
- Total Assets 133.7 Mil
-
Adj. Expense Ratio
- Expense Ratio 1.160%
- Distribution Fee Level High
- Share Class Type Institutional
- Category Health
- Investment Style Large Growth
- Min. Initial Investment —
- Status Open
- TTM Yield 0.24%
- Turnover 28%
USD | NAV as of Apr 24, 2024 | 1-Day Return as of Apr 24, 2024, 10:18 PM GMT+0
Morningstar’s Analysis HBGHX
Will HBGHX outperform in future?
Get our overall rating based on a fundamental assessment of the pillars below.
People Pillar
Parent Pillar
- Current Portfolio Date
- Equity Holdings —
- Bond Holdings —
- Other Holdings —
- % Assets in Top 10 Holdings 43.3
Top 10 Holdings
|
% Portfolio Weight
|
Market Value USD
|
Sector
|
---|---|---|---|
Eli Lilly and Co | 10.92 | 15.5 Mil | Healthcare |
UnitedHealth Group Inc | 6.79 | 9.6 Mil | Healthcare |
Merck & Co Inc | 6.37 | 9.0 Mil | Healthcare |
Danaher Corp | 3.90 | 5.5 Mil | Healthcare |
Stryker Corp | 2.83 | 4.0 Mil | Healthcare |
Boston Scientific Corp | 2.80 | 4.0 Mil | Healthcare |
Thermo Fisher Scientific Inc | 2.51 | 3.6 Mil | Healthcare |
HCA Healthcare Inc | 2.51 | 3.5 Mil | Healthcare |
AbbVie Inc | 2.39 | 3.4 Mil | Healthcare |
Vertex Pharmaceuticals Inc | 2.32 | 3.3 Mil | Healthcare |